| Document |
Document Title |
|
WO/1985/003298A1 |
Novel vitamin D derivatives, isomers of 25-hydroxyvitamin D2 and 1alpha, 25-dihydroxyvitamin D2 characterized by a double bond at the 23, 24-position. The compounds are characterized by vitamin D-like activity as assessed by competitive ...
|
|
WO/1985/002841A1 |
9-halogen-DELTA2-prostaglandine derivatives having the general formula (I), wherein Hal may be a fluorine or chlorine atom in alpha or beta position; R1 may be the rest OR2, R2 being a hydrogen atom, an alkyl, a cycloalkyl, an aryl or a ...
|
|
WO/1985/002189A1 |
Preparation of hydroxylated compounds of the vitamin D2 series and specifically to a process for synthesizing 1alpha,25-dihydroxy vitamin D2, 1beta,25-dihydroxyvitamin D2, their corresponding 5,6-trans isomers and the C-24 epimers of the...
|
|
WO/1985/001728A1 |
A process for preparing prostaglandin D2's in good yields, which comprises treating 7-hydroxyPGF2alpha's with thiocarbonylimidazole or an analogue thereof, subjecting the product to deoxidation of the hydroxy group in position 7, convers...
|
|
WO/1985/001291A1 |
Novel 1,23-dihydroxyvitamin D compounds, a process for preparing such compounds of novel intermediates in such process. As indicated by its binding affinity for the 1alpha,25-dihydroxyvitamin D3 receptor protein, the compounds of this in...
|
|
WO/1985/000818A1 |
New derivative of vitamin D, 23,23-difluoro-25-hydroxycholecalciferol, a method for preparing said compound and various new intermediates utilized in such process. The compound is characterized by vitamin D-like activity as evidenced by ...
|
|
WO/1985/000819A1 |
New derivative of vitamin D, 23,23-difluoro-1,25-dihydroxycholecalciferol. The compound is characterized by vitamin D-like activityas evidenced by its ability to increase intestinal calcium transport. It is further characterized by its r...
|
|
WO/1985/000367A1 |
11-halogene-prostane derivatives of the general formula (I), wherein X is F, Cl or Br; R1 is CH2OH or (II) wherein R2 is a hydrogen atom, a rest of alkyl, cycloalkyl, aryl, phenacyl or heterocyclic rest; A is a group -CH2-CH2- or cis -CH...
|
|
WO/1984/004917A1 |
7-Fluoroprostaglandins represented by formula (I), wherein R1 represents H or C1-10 alkyl, R2, R3, and R4 each represents H or the same or different protective group, and R5 represents C3-7, straight-chain, branched or cyclic alkyl.
|
|
WO/1984/004527A1 |
Novel derivatives of vitamin D2 and more specifically 1alpha,25-dihydroxylated compounds of the vitamin D series. A process for the preparation of such derivatives is also provided as are certain intermediates in such process. The invent...
|
|
WO/1984/001944A1 |
Photochemical reactions are conducted using floating polymer beads on the surface of a moving body of water. The polymer bead is impregnated with a reactant, floated on the water in direct sunlight so as to expose the reactant to solar r...
|
|
WO/1984/001577A1 |
A process for preparing a cycloaddition compound, which comprises reacting ketene with a carbonyl group-containing compound having formula (I), which contains a highly electron-attractant group in the alpha-position relative to the carbo...
|
|
WO/1984/001155A1 |
Hydroxylated derivatives of vitamin D2., processes for preparing such compounds, intermediates utilized in such processes and certain isotopically labelled vitamin D2 compounds. The vitamin D2 derivatives would find application in the tr...
|
|
WO/1984/000550A1 |
New fluorinated derivatives of vitamin D among which are 24-fluoro-alpha, 25-dihydroxyvitamin D3 and 24-fluoro-1alpha, 25-dihydroxy-5,6-trans-vitamin D3. The compounds should be a ready substitute for 1alpha,25-dihydroxyvitamin D where t...
|
|
WO/1983/002273A1 |
Novel compounds have a formula (I)$(10,)$wherein$(6,)$represents a bicyclo AD2,2,1 BD hept-2Z-ene, bicyclo AD2,2,1 BD heptane, 7-oxa-bicyclo AD2,2,1 BD hept-2Z-ene, 7-oxa-bicyclo AD2,2,1 BD heptane, bicyclo AD 2,2,2 BD oct-2Z-ene or bicy...
|
|
WO/1983/002103A1 |
The injection cartridge comprises two containers (1, 2) slidingly fitted one into the other. The rod (8) comprises a smooth front portion (9) and a threaded rear portion (10) separated by a threaded intermediate portion (11). The contain...
|
|
WO/1983/000335A1 |
New derivative of vitamin D, 26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxycholecalcife
rol, a process for preparing the same, and novel intermediate compounds. The compound is characterized by vitamin D-like activity substantially gre...
|
|
WO/1982/004249A1 |
Compounds of the formula: (FORMULA) wherein A represents the residue of the dienophile, obtainable as a Diels-Alder adduct of beta-farnesene and a dienophile, which are used in pest control, or which are converted to a derivative of said...
|
|
WO/1982/003864A1 |
A process for preparing biologically active 1(Alpha)-hydroxyvitamin D compounds from vitamin D compounds by hydroxylation at carbon 1 and subsequent photochemical isomerization, and novel intermediates and products resulting from this pr...
|
|
WO/1982/002893A1 |
New derivatives of vitamin D3, specifically, 1(Alpha), 25-dihydroxy-2(Beta)-fluorocholecalciferol. The compound is characterized by vitamin D-like activity as measured by its ability to stimulate intestinal calcium transport, mobilizatio...
|
|
WO/1982/000465A1 |
Methods for preparing the various isomeric forms of 25-hydroxyvitamin D3-26, 23-lactone utilizing cyanohydrin formation with readily prepared steroid materials followed by actinic radiation of the products and recovery of the desired 25-...
|
|
WO/1982/000142A1 |
Novel compounds have a formula (I) (FORMULA) wherein (FORMULA) represents a bicyclo (2, 2, 1)hept-2Z-ene, bicyclo(2, 2, 1)heptane, 7-oxabicyclo(2, 2, 1)hept-2Z-ene, 7-oxabi-cyclo(2, 2, 1)heptane, bicyclo(2, 2, 2)oct-2Z-ene or bicyclo(2, ...
|
|
WO/1981/001002A1 |
Prostaglandin and prostacyclin compounds which are fluorine substituted in any one or more of the following positions, 4, 4; 7, 7; 10, 10; and 5.
|
|
WO/1980/002502A1 |
New vitamin D derivatives as well as new intermediate compounds derived during the processes for preparing such new derivatives. The new derivatives have been identified as 1(Alpha)-hydroxy-25-keto-27-nor-vitamin D3 and its acylates. 1(A...
|
|
WO/1980/002562A1 |
Isotopically labeled vitamin D compounds, including radiolabeled vitamin D compounds of high specific activity, methods for their preparation, and novel intermediates in their synthesis. The radiolabeled vitamin D compounds are character...
|
|
WO/1980/002028A1 |
New derivatives of vitamin D,24,24-difluoro-1(Alpha),25-dihydroxycholecalciferol and 24,24-difluoro-1(Alpha),25-dihydroxy-5,6-trans-cholecalcifer
ol and processes for preparing the same. The compounds are characterized by vitamin D-like ...
|
|
WO/1980/001915A1 |
New derivative of vitamin D3,24,24-difluoro-25-hydroxycholecalciferol. The compound is characterized by vitamin D-like activity in its ability to increase intestinal calcium transport, increase serum calcium and inorganic phosphorous con...
|
|
WO/1980/001379A1 |
New derivatives of vitamin D3, 1(Alpha), 3(Beta)-dihydroxy-9,10-seco-24-norchola-5,7,10(19)-trien-23 oic acid and esters thereof. The compound is characterized by antirachitic (vitamin D-like) activity and would find application in disea...
|
|
WO/1980/000338A1 |
New fluorine-substituted vitamin D compounds, methods for preparing such compounds and fluorinated intermediate compounds used in such methods. The fluorine-substituted vitamin D compounds of this invention are characterized by vitamin D...
|
|
WO/1980/000339A1 |
New fluorine-substituted vitamin D compounds, methods for preparing such compounds and new fluorinated intermediate compounds used in such methods. The fluorine-substituted vitamin D compounds of this invention are characterized by vitam...
|
|
WO/1979/000513A1 |
The principal object of the invention is to provide a method for directly introducing an oxygen function at carbon 1 of the vitamin D molecule or precursors or derivatives thereof which comprises subjecting such molecule to allylic oxida...
|
|
JP7341464B2 |
To provide a redox photocatalyst applicable to a wide range of reactions.The redox photocatalyst comprises a compound represented by the general formula (I) or (II) in the figure. [In the formula, Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7 and Ar...
|
|
JP2023126188A |
To provide a compound that can be readily used in the evaluation of VDR binding affinity, reflecting the actual VDR binding affinity of a candidate compound.Provided herein is a compound represented by the formula (I) (where R1 is a subs...
|
|
JP2023095257A |
To provide a compound useful for the analysis of a vitamin D compound.For example, an alkyne compound 10 prepared by the following reaction is illustrated.SELECTED DRAWING: None
|
|
JP2023061920A |
To provide a new vitamin D derivative that is useful for treating or preventing psoriasis or cancer.Examples of vitamin D derivatives disclosed herein are compounds having structures illustrated below.SELECTED DRAWING: None
|
|
JP2023503054A |
Co-crystals of a compound of formula (I) or a compound of formula (II) and a hydrogen bond donor coformer that is a phenolic compound are provided. Compositions comprising the co-crystals and personal care products comprising the composi...
|
|
JP7193521B2 |
It is an object of the present invention to provide methods for producing vitamin D that gives improved yields and reduced side product contamination. In various aspects, these methods provide for production of vitamin-D2 using ergostero...
|
|
JP2022531835A |
The present invention is an improved photochemical synthesis of vitamin D3 with 7-dehydrocholesterol alone or in combination with a sterol precursor at high yields and low impurity levels in the presence of a photosensitizer of formula I...
|
|
JP2022531081A |
The present invention discloses an improved method for producing vitamin D3 from 7-dehydrocholesterol (7-DHC), and a simple method for recovering unreacted 7-DHC for further reuse. .. The invention further describes methods for the isola...
|
|
JP7072676B2 |
The present invention provides a 25-hydroxycholecalciferol monohydrate crystal, a preparation method thereof, and a microemulsion using the 25-hydroxycholecalciferol monohydrate crystal. The X-ray powder diffraction spectrum of the 25-hy...
|
|
JP2022514401A |
R1And R2At least one of them represents F, the other is selected from H and F, and R3The 2-fluorinated bile acid compounds of general formula (I) as defined herein are useful in the treatment and prevention of neurodegenerative diseases,...
|
|
JP2022011440A |
To provide a novel compound having a secosteroid structure, which is a common structure of vitamin D.The present invention relates to a compound represented by the following formula (where R1 is an OH group, O-C2-C18 acyl group, or a gly...
|
|
JP6971966B2 |
Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D3, (20S)-1α-hydroxy-2-met...
|
|
JP2021167319A |
To provide 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs.Particularly, there are disclosed 1α-hydroxy-2-methylene-vitamin D3, (20S)-1α-hydroxy-2-...
|
|
JP6817208B2 |
It is an object of the present invention to provide methods for producing vitamin D that gives improved yields and reduced side product contamination. In various aspects, these methods provide for production of vitamin-D2 using ergostero...
|
|
JP6812405B2 |
Pharmaceutically acceptable cholecalciferol sulfate salts are used for combating vitamin D3 deficiency. New cholecalciferol sulfate salts as well as pharmaceutical compositions of the pharmaceutically acceptable cholecalciferol sulfate s...
|
|
JP2020537664A |
Compound (22E)-(24R) -2-methylene-22-dehydro-1α, 24,25-trihydroxy-19-nor-vitamin D3Discloses a method of purifying a compound to obtain a compound in crystalline form. The method is generally in a solvent containing ethyl acetate and he...
|
|
JP2020200300A |
To acquire an eldecalcitol crystal form with high yield, high purity and good stability.Eldecalcitol represented by formula I is dissolved in one or more solvents selected from among methanol, ethanol, acetonitrile, acetone and tetrahydr...
|
|
JP6800748B2 |
The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corres...
|
|
JP6784963B2 |
The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesit...
|
